Clinical Trial: Phase II Study of Gene Therapy for Duchenne Muscular Dystrophy (DMD-GT-001)

Trial Design: Single-arm, open-label study of systemic gene therapy
Participants: 24 boys aged 4-7 years with confirmed DMD mutations
Intervention: Single IV infusion of AAV-microdystrophin vector
Primary Endpoint: Change in North Star Ambulatory Assessment (NSAA) at 12 months

Results Summary:
- NSAA score improvement: +2.4 points vs historical decline of -1.8 points
- Functional improvement in 83% of participants
- Dystrophin expression: Detected in 92% of muscle biopsies
- Mean dystrophin level: 41% of normal (range 15-74%)

Safety Profile:
- Transient elevation of liver enzymes: 67% (all resolved with steroids)
- Complement activation: 25% (managed with prophylactic steroids)
- No serious adverse events related to treatment
- Transient thrombocytopenia: 17%
- Myalgia and fatigue: 42% (resolved within 2 weeks)

Biomarker Analysis:
- Creatine kinase reduction: 65% decrease from baseline
- Improved muscle fiber architecture on histology
- Reduced inflammatory markers in muscle tissue
- Functional dystrophin confirmed by immunofluorescence

Long-term Follow-up (24 months):
- Sustained functional improvement in 75% of patients
- Continued dystrophin expression in repeat biopsies
- No late-onset safety signals
- Quality of life improvements reported by families

Regulatory Pathway:
- FDA granted Breakthrough Therapy designation
- EMA PRIME eligibility confirmed
- Accelerated approval pathway under consideration
- Orphan drug status in US and EU

Market Considerations:
- Estimated treatment cost: $2-3 million per patient
- Target population: ~6,000 eligible patients globally
- Potential market size: $12-18 billion
- Manufacturing capacity: Major bottleneck for commercialization